Fortune 100 CFO Mr. Luc Vanhal Joins Caleco Pharma Corp.

LONG VALLEY, NEW JERSEY--(Marketwire - June 14, 2010) - (OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) (www.calecopharmacorp.com) Caleco Pharma Corp. (the “Company” or “Caleco”), is a diversified healthcare company with biopharmaceutical and consumer health products development programs. The company identifies and develops products derived from natural sources including plant extracts, functional oils and probiotics, and today announces that Mr. Luc Vanhal has joined the company in the role of Chief Financial Officer. Mr. Vanhal’s stellar career brings experience as CFO and COO for NYSE and NASDAQ companies as well as Board of Director experience for many smaller emerging public companies.

“I am excited about joining the team at Caleco Pharma at this key juncture in the Company’s growth. Our broad product line, coupled with our dual pathways to market should help us ramp up the company’s revenues very rapidly,” said Mr. Vanhal. “There is a direct transfer of sourcing, manufacturing, marketing and sales expertise from my previous company to Caleco. We have built strong companies in the past and I am looking forward to repeating that experience here at Caleco.”

Mr. Vanhal was most recently the CFO and COO of Guthy-Renker, one of the world’s largest direct response media companies with sales of more than $1.5 billion. The company develops, manufactures and markets celebrity endorsed products in areas such as skin care, cosmetics, hair care and fitness products. Mr. Vanhal’s responsibilities included Finance, Accounting, IT, Human Resources, Customer Service, Inbound Telemarketing, Vendor management, Procurement, Manufacturing, Fulfillment, Distribution and Warehousing Prior to Guthy-Renker, he was Chief Operating and Financial Officer for Belkin Corporation, a technology leader in connectivity solutions, with overall worldwide responsibility for Finance, Accounting, IT, Procurement, Supply Chain, Human Resources, Strategic Planning, Distribution & Warehousing, and Legal departments. Belkin has offices in the US, Europe, Singapore, China and Australia.

Mr. Vanhal was CFO and then President and COO of Vivendi Universal Games, the gaming unit of the French media and utilities conglomerate, Vivendi. Mr. Vanhal capped a ten year career at The Walt Disney Company as CFO of Disney’s Consumer Products Division - Worldwide, a $3 Billion dollar division of Disney.

Mr. Vanhal currently sits on the Board of Interplay Entertainment Corporation as member of the Audit Committee and the Compensation Committee. He was until recently on the Board of Directors of ViewSonic Corporation, where he was Chairman of the Audit Committee and a Member of the Governance and the Compensation committees.

About Caleco Pharma Corp.

http://www.calecopharmacorp.com/

Caleco Pharma is focused on the research, development and sales of its pipeline of over-the-counter and prescription medications including its proprietary antiviral and “Liver Health” OTC formulations. Caleco Pharma is developing Dermatological Products based on the active ingredients found in its proprietary formulation. To date, Caleco Pharma’s intellectual property covering the Liver Health formulations and derivatives consists of patent applications in the United States, Europe and Canada and four European Drug Master File applications.

Caleco Pharma’s shares are traded in the United States on the OTC Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock Exchange (FRANKFURT: T3R)(WKN: A0N9Y0).

This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) Caleco will be granted a patent in connection with its current patent applications in the United States, Europe and Canada; (ii) Caleco Pharma will be able to manufacture and produce its products or that its products will be effective; (iii) Caleco will be able to carry out any pre-clinical or clinical trials of its products; (iv) Caleco will be able to obtain additional financing in order to meet the costs of the clinical studies of the “Liver Health” formulation; and (v) Caleco will be able to control the costs of the clinical studies of the “Liver Health” formulation. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.